Senior GSK plc (GSK) leaders acquire Ordinary Shares through Share Reward Plan

Rhea-AI Filing Summary

GSK plc reported that several senior leaders and one person closely associated acquired small amounts of Ordinary Shares under the company’s Share Reward Plan. On 11 August 2026, each of eight senior individuals and one PCA acquired partnership and matching shares on the London Stock Exchange at £19.3496 per share.

Key Figures

Acquisition price: £19.3496 per Ordinary Share Shares per executive (most): 14 Ordinary Shares Shares for Victoria Whyte: 12 Ordinary Shares +1 more

4 metrics

Acquisition price £19.3496 per Ordinary Share Price for all Share Reward Plan acquisitions on 11 August 2026

Shares per executive (most) 14 Ordinary Shares 7 partnership and 7 matching shares for eight reported individuals

Shares for Victoria Whyte 12 Ordinary Shares 6 partnership and 6 matching shares under the Share Reward Plan

Transaction date 2026-08-11 Date of all reported Share Reward Plan acquisitions

Key Terms

PDMR, person closely associated, Share Reward Plan, Ordinary Shares

4 terms

PDMR regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

person closely associated regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

Share Reward Plan financial

"Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan"

Ordinary Shares financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider share activity did GSK (GSK) disclose in this report?

GSK disclosed that several senior managers and one person closely associated acquired Ordinary Shares under its Share Reward Plan on 11 August 2026 at £19.3496 per share on the London Stock Exchange.

Which GSK (GSK) executives acquired shares under the Share Reward Plan?

Participants included Lynn Baxter, Julie Brown, James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte, and PCA Neil Falkingham, all acquiring Ordinary Shares under GSK’s Share Reward Plan.

How many GSK (GSK) shares were acquired by each participating executive?

Most participating executives acquired 14 Ordinary Shares each (7 partnership and 7 matching shares). Victoria Whyte acquired 12 Ordinary Shares (6 partnership and 6 matching shares) under the Share Reward Plan.

At what price were GSK (GSK) Share Reward Plan shares acquired?

All reported acquisitions under the Share Reward Plan were made at a price of £19.3496 per Ordinary Share. This price applied to both partnership shares and matching shares purchased on 11 August 2026.

On which market did the GSK (GSK) insider share acquisitions occur?

The acquisitions of GSK Ordinary Shares by senior managers and a PCA under the Share Reward Plan were executed on the London Stock Exchange (XLON) on 11 August 2026 at £19.3496 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/13/2026 - 11:33 AM Accepted by SEC EDGAR 08/13/2026 - 11:33 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	6 (partnership shares)
		£19.3496	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.3496
e)	Date of the transaction	2026-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 13, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc